As optimal treatment modalities for neovascular AMD would target the multiple mechanisms of AMD-associated vision loss, including neovascularization, inflammation, and fibrosis, our results support PAF-R as an attractive target in the treatment of AMD, as well ad other ocular wound healing processes, such as proliferative diabetic retinopathy and retinopathy of prematurity. This evidence concerns the gene PTAFR and age-related macular degeneration.